Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Frontiers Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection

Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies - Kelsey Baron, Justin C Moser, Shiven Patel, Kenneth F Grossmann

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination

Full article: Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma